S. Deheneffe

CHU Dinant Godinne UCL Namur

Papers

1

Total Citations

7

H-Index

1

About

S. Deheneffe is a leading clinical researcher in head and neck oncology, with a focused expertise in the treatment of supraglottic squamous cell carcinoma. Their major contribution is spearheading the landmark SUPRA-QoL study, a prospective evaluation that rigorously compares oncological outcomes, functional results, quality of life, and cost-effectiveness of advanced, organ-sparing therapeutic technologies against traditional total laryngectomy. This work is pivotal in demonstrating that modern techniques can achieve equivalent prognoses with significantly reduced morbidity. With their most-cited paper already accumulating 7 citations shortly after publication in 2023, Deheneffe’s research is rapidly shaping clinical guidelines. By providing robust evidence for function-preserving alternatives, they are directly improving patient survivorship and setting a new standard for evidence-based, patient-centered care in head and neck cancer treatment.

Research Focus

Key Achievements

1
H-Index
1
Papers
7
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Treatment of supraglottic squamous cell carcinoma with advanced technologies: observational prospective evaluation of oncological outcomes, functional outcomes, quality of life and cost-effectiveness (SUPRA-QoL)
7 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: CHU Dinant Godinne UCL Namur

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago